|About Us||Patients, Families & Visitors||For Health Professionals||Careers||Research & Training||Ways to Give|
We hypothesize that multi-modality imaging techniques will be able to comprehensively characterize the biologic, functional and morphologic characteristics of prostate cancer in a spatially accurate fashion to guide minimally invasive, low morbidity techniques for the diagnosis and treatment of prostate cancer.
Our team will test this hypothesis by concentrating our efforts on four key Research Themes along a translational, pre-clinical to clinical development pathway.
Through Theme A: Pre-clinical Imaging we will develop and validate new imaging methods in animal models to measure important “physiologic switches” involved in PCa progression that could be subsequently applied to humans using the validation methodology developed in Themes B-D.
In Theme B: Fiducial Hybrid Imaging Fusion, we will develop the ability to fuse morphologic and biologic imaging data to create “hybrid imaging maps and models”(HIMM) that can be used to non-invasively predict the distribution of biologically significant sub-volumes within the prostate with millimetre accuracy.
In Theme C: Biologic Validation of Hybrid Imaging, we will validate the HIMM in a volumetric and fiducially accurate fashion using the three-dimensional (3D) tissue distribution of cancer in radical prostatectomy (RP) specimens as a gold standard.
Theme D: Hybrid Imaging-augmented Diagnostics and Therapies will evaluate the potential impact of HIMM on outcomes and quality of life using therapy modeling and pilot trials.